Drug Profile
Midafotel
Alternative Names: D-CPPene; SDZ EAA 494Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Novartis
- Developer BTG; Novartis
- Class
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Brain injuries; Cognition disorders; Epilepsy
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 19 Jul 2010 Discontinued - Phase-I for Cognition disorders in Switzerland (unspecified route)
- 19 Jul 2010 Discontinued - Phase-III for Brain injuries in Switzerland (unspecified route)